Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloom, R. D.
Right arrow Articles by Mange, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloom, R. D.
Right arrow Articles by Mange, K. C.
J Am Soc Nephrol 13:1374-1380, 2002
© 2002 American Society of Nephrology

Association of Hepatitis C with Posttransplant Diabetes in Renal Transplant Patients on Tacrolimus

Roy D. Bloom*, Vinaya Rao{dagger}, Francis Weng*, Robert A. Grossman*, Debbie Cohen* and Kevin C. Mange*{ddagger}

*Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; {dagger}Division of Nephrology, University of Miami, Miami, Florida; and {ddagger}Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.

Correspondence to: Dr. Roy D. Bloom, Renal-Electrolyte and Hypertension, 700 CRB, University of Pennsylvania, 422 Curie Blvd, Philadelphia, PA 19104. Phone: 215-662-4643; Fax: 215-349-5703; E-mail: rdbloom{at}mail.med.upenn.edu

ABSTRACT. Posttransplant diabetes mellitus (PTDM) remains a common complication of immunosuppression. Although multiple risk factors have been implicated, none have been clearly identified as predisposing to the increased PTDM frequency observed in patients on tacrolimus. Hepatitis C virus (HCV) has been associated with diabetes and is a significant renal transplant comorbidity. In this study, records of 427 kidney recipients who had no known diabetes before transplantation were retrospectively examined. A multivariate logistic regression model was fit with covariates that had unadjusted relationships with PTDM to examine the independent relationship of HCV and the odds of development of PTDM by 12 mo posttransplant. A potential interaction between HCV and the use of tacrolimus as maintenance therapy on the odds of the development of PTDM was examined. Overall, PTDM occurred more frequently in HCV+ than HCV- patients (39.4% versus 9.8%; P = 0.0005). By multivariate logistic regression, HCV (adjusted odds ratio [OR], 5.58; 95% confidence interval [CI], 2.63 to 11.83; P = 0.0001), weight at transplantation (adjusted OR 1.028; 95% CI, 1.00 to 1.05; P = 0.001), and tacrolimus (adjusted OR, 2.85; 95% CI, 1.01 to 5.28; P = 0.047) were associated with PTDM. A significant interaction (P = 0.0001) was detected between HCV status and tacrolimus use for the odds of PTDM. Among the HCV+ cohort, PTDM occurred more often in tacrolimus-treated than cyclosporine A–treated patients (57.8% versus 7.7%; P < 0.0001). PTDM rates in HCV- patients were similar between the two calcineurin inhibitors (10.0% versus 9.4%; P = 0.521, tacrolimus versus cyclosporine A). In conclusion, HCV is strongly associated with PTDM in renal transplant recipients and appears to account for the increased diabetogenicity observed with tacrolimus.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Covic, D. Abramowicz, A. Bruchfeld, G. Leroux-Roels, D. Samuel, W. van Biesen, C. Zoccali, F. Zoulim, R. Vanholder, and on behalf of the ERA-EDTA ERBP Advisory Board
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 719 - 727.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1411 - 1418.
[Full Text] [PDF]

Home page
 CJASNHome page
J. S. Gill
Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S29 - S37.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. D. Bloom and M. F. Crutchlow
New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. D. Bloom and P. P. Reese
Chronic Kidney Disease after Nonrenal Solid-Organ Transplantation
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3031 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Kamar, C. Mariat, M. Delahousse, J. Dantal, A. Al Najjar, E. Cassuto, N. Lefrancois, O. Cointault, G. Touchard, F. Villemain, et al.
Diabetes mellitus after kidney transplantation: a French multicentre observational study
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1986 - 1993.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. E. Burroughs, K. L. Lentine, S. K. Takemoto, J. Swindle, G. Machnicki, K. Hardinger, D. C. Brennan, W. D. Irish, and M. A. Schnitzler
Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 517 - 523.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
N. A. Terrault and D. B. Adey
The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 563 - 575.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. F. Crutchlow and R. D. Bloom
Transplant-Associated Hyperglycemia: A New Look at an Old Problem
Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. D. Crook, S. Penumalee, B. Gavini, and K. Filippova
Hepatitis C Is a Predictor of Poorer Renal Survival in Diabetic Patients
Diabetes Care, September 1, 2005; 28(9): 2187 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Transplantation and Islet Topics
Diabetes Care, January 1, 2005; 28(1): 213 - 219.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. C. Abbott, K. L. Lentine, J. R. Bucci, L. Y. Agodoa, J. M. Koff, K. C. Holtzmuller, and M. A. Schnitzler
Impact of Diabetes and Hepatitis after Kidney Transplantation on Patients Who Are Affected by Hepatitis C Virus
J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3166 - 3174.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. C. Magee and M. Pascual
Update in Renal Transplantation
Arch Intern Med, July 12, 2004; 164(13): 1373 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. C. Abbott, C. M. Yuan, A. J. Taylor, D. F. Cruess, and L. Y. C. Agodoa
Early Renal Insufficiency and Hospitalized Heart Disease after Renal Transplantation in the Era of Modern Immunosuppression
J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2358 - 2365.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673